Strides Pharma Science Ltd
Strides Pharma Science Ltd (STAR) last traded at ₹986, a market capitalisation of ₹9,091 crore, on a P/E of 15.7. Over the past 52 weeks the stock has ranged between ₹769 and ₹1,231. Strides Pharma Science Ltd last reported results for the quarter ended Jun 2026, with sales of ₹1,265 crore and net profit of ₹165 crore. Figures are as of 25 Aug 2026 and are not real time.
Strides Pharma Science Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Strides Pharma Science Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹1,265 cr, up 12.9% from ₹1,120 cr a year earlier. Net profit was ₹165 cr, up 55.7% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 1,167 | 1,154 | 1,190 | 1,120 | 1,221 | 1,195 | 1,323 | 1,265 |
| Expenses | 983 | 943 | 973 | 902 | 990 | 959 | 1,084 | 1,037 |
| Operating profit | 184 | 210 | 218 | 218 | 231 | 236 | 240 | 228 |
| OPM % | 16% | 18% | 18% | 19% | 19% | 20% | 18% | 18% |
| Other income | 25 | 4 | -12 | 0 | 18 | 104 | 3 | 68 |
| Interest | 74 | 52 | 50 | 47 | 46 | 43 | 42 | 41 |
| Depreciation | 48 | 48 | 49 | 49 | 50 | 51 | 53 | 56 |
| Profit before tax | 86 | 114 | 106 | 122 | 153 | 245 | 148 | 200 |
| Tax % | 16% | 21% | 20% | 13% | 14% | 15% | 13% | 17% |
| Net profit | 72 | 90 | 86 | 106 | 132 | 208 | 129 | 165 |
| EPS (₹) | 7.81 | 9.54 | 8.91 | 10.80 | 13.84 | 21.93 | 13.77 | 17.02 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Strides Pharma Science Ltd annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 3,316 | 3,070 | 3,688 | 3,890 | 4,565 | 4,859 | 5,004 |
| Operating profit | 537 | -131 | 145 | 528 | 803 | 925 | 935 |
| OPM % | 16% | -4.3% | 3.9% | 14% | 18% | 19% | 19% |
| Net profit | 258 | -474 | -212 | -94 | 3,598 | 575 | 634 |
| EPS (₹) | 29.93 | -51.25 | -22.44 | -7.68 | 389.75 | 60.34 | 66.56 |
TTM is the trailing twelve months to the most recent quarter.
Strides Pharma Science Ltd growth and returns
- 10 Years
- 5%
- 5 Years
- 8%
- 3 Years
- 10%
- TTM
- 8%
- 10 Years
- 16%
- 5 Years
- 20%
- 3 Years
- 71%
- TTM
- 55%
- 10 Years
- 8%
- 5 Years
- 30%
- 3 Years
- 69%
- 1 Year
- 10%
- 10 Years
- 22%
- 5 Years
- 31%
- 3 Years
- 57%
- Last Year
- 20%
Strides Pharma Science Ltd shareholding pattern
Promoters held 27.91% at Jun 2026, broadly unchanged since Jun 2025. FIIs 28.40% and DIIs 15.42%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 25.84% | 26.82% | 28.30% | 28.30% | 27.86% | 27.86% | 27.91% | 27.91% |
| FIIs | 30.08% | 28.48% | 28.32% | 28.02% | 28.51% | 29.52% | 28.68% | 28.40% |
| DIIs | 18.24% | 16.92% | 13.72% | 13.30% | 12.98% | 13.02% | 14.44% | 15.42% |
| Government | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% |
| Public | 25.83% | 27.78% | 29.65% | 30.38% | 30.62% | 29.59% | 28.96% | 28.28% |
| No. of shareholders | 96,009 | 1,14,236 | 95,125 | 92,889 | 91,206 | 85,589 | 86,616 | 94,850 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Cruxal coverage of Strides Pharma Science Ltd
Strides Pharma Science Ltd corporate filings
- Strides receives USFDA Establishment Inspection Report (EIR) for flagship facility in BengaluruCompany Updatemedium impact
Cruxal's analysis: Strides Pharma Science has received the Establishment Inspection Report (EIR) from the…
Read the full analysis - Voting results along with Scrutinizers report for 35th AGM.AGM/EGMlow impact
Cruxal's analysis: Strides Pharma Science Limited has successfully concluded its 35th Annual General Meeting…
Read the full analysis - Proceedings of 35th Annual General Meeting of the CompanyAGM/EGMlow impact
Cruxal's analysis: Strides Pharma Science Limited successfully conducted its 35th Annual General Meeting on…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Strides Pharma Science Ltd
Cruxal reads every Strides Pharma Science Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.